# Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3

> **NCT01634503** · PHASE1 · COMPLETED · sponsor: **Genexine, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Cervical Intraepithelial Neoplasia 3

## Interventions

- **GENETIC:** GX-188E administered by electroporation

## Key facts

- **NCT ID:** NCT01634503
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2014-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01634503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01634503, "Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01634503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*